Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Speech biomarker for cognition: a novel marker for AD clinical trial screening

Nicklas Linz, MS, ki:elements, Saarbrücken, Germany, presents the novel speech biomarker for cognition (SB-C), developed by ki:elements. The 10-minute SB-C is delivered over the phone and consists of two standard neuropsychological assessments: the Rey Auditory Verbal Learning Test (RAVLT) and the Semantic Verbal Fluency task (SVF). 85 features of speech data are automatically extracted and analyzed, producing individual scores for memory, executive function, and processing speed, as well as one global cognition score which summarizes these three measures. The SB-C rating was found to correlate well with Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) scores. Furthermore, over a 12-month period, patients who experienced significant cognitive decline also demonstrated a decline in SB-C rating. The system is currently being used in the pre-screening of patients for the AUTONOMY Phase II clinical trial (NCT04619420). This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.